Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jun 30, 2026 → Dec 31, 2026
See other at-risk trials from M.D. Anderson Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jun 30, 2026 to Dec 31, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description revised
  2. Re-verified, no change to tracked fieldsv11
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 400 to confirmed 182
    • Site details revised
    v10
  4. Primary and study completion dates: Jun 30, 2024 to Jun 30, 2026v9
  5. Re-verified, no change to tracked fieldsv8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary and study completion dates: May 1, 2023 to Jun 30, 2024v7
  2. Re-verified, no change to tracked fieldsv6
  3. Primary and study completion dates: May 1, 2022 to May 1, 2023v5
  4. Primary and study completion dates: May 1, 2021 to May 1, 2022
    • Site contact updated
    v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 30, 2020 to Jul 18, 2020
    • Site details revised
    v3
  6. Start date: Feb 28, 2020 to Apr 30, 2020v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial studies the attitudes and beliefs of high risk patients and caregivers regarding the prescription of intranasal naloxone spray for opioid overdose. Knowledge regarding high risk patients' and caregivers' beliefs and attitudes regarding co-prescription of naloxone spray with opioids may help to identify barriers to prescribing and helping tailor the education to better meet the needs of patients and caregivers.
Trial Details
NCT Number NCT04129138
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Caregiver, Patient
Enrollment 182 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov